Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com

25 Nov 2022
www.businesswire.com
Phase 2Phase 3Clinical ResultPhase 1
DUBLIN--(BUSINESS WIRE)--The "Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
'Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2022'
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Chronic Hepatitis Delta Virus (HDV) Infection commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis Delta Virus (HDV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis Delta Virus (HDV) Infection.
Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Chapters
This segment of the Chronic Hepatitis Delta Virus (HDV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs
Eiger's lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.
Janssen "breakthrough" drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral class molecule designed to treat HVB and HVD infection via RNA interference mechanism. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.
Chronic Hepatitis Delta Virus (HDV) Infection: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Hepatitis Delta Virus (HDV) Infection drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III include, Eiger Biopharmaceuticals.
Phases
This report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II and Phase I/II)
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Chronic Hepatitis Delta Virus (HDV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
Subcutaneous
Intravenous
Oral
Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
Small molecules
Natural metabolites
Monoclonal antibodies
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Hepatitis Delta Virus (HDV) Infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis Delta Virus (HDV) Infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis Delta Virus (HDV) Infection drugs.
Chronic Hepatitis Delta Virus (HDV) Infection Report Insights
Chronic Hepatitis Delta Virus (HDV) Infection Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Chronic Hepatitis Delta Virus (HDV) Infection Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Products
Lonafarinib
VIR 2218
VIR 3434
Nivolumab
HH 003
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/wr0q5q
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.